We hope these tissues unlock some of the ‘secrets’ behind breast cancer
Professor Valerie Speirs is co-principal investigator of the Breast Cancer Now Tissue Bank. Here Valerie and Edward Jones, our research communications officer, discuss how the Bank has grown over the past 10 years to become a phenomenal medical resource.
It’s about striving for improved outcomes for patients in future
Valerie is a laboratory scientist with a PhD in cancer biology. She’s been working in breast cancer research for more than 25 years, and helped create the Tissue Bank Project.
To date, the Tissue Bank has collected almost 127,000 samples from people who are at risk or affected by breast cancer, and already more than 12,000 of those samples have been allocated to research projects.
Among the projects Val and Edward talk about in this episode is the Cell Atlas, and how that’s transforming the way researchers understand the biology of disease. It could, Val explains, lead to major advances in the way that breast cancer is diagnosed and treated in the future.
The Tissue Bank has grown over the last 10 years to become a phenomenal resource
Everyone’s experience is unique to them. This podcast contains the personal story and experience of the speaker, rather than that of Breast Cancer Now.
You can subscribe to The Breast Cancer Now Podcast via your preferred podcast provider. This is where you'll hear the personal stories of people who have experienced breast cancer, as well as discussions with healthcare professionals and researchers.
Scientists, based at the Queen Mary University of London, have discovered a new mechanism that signals which Ductal Carcinoma in Situ (DCIS) tumours may progress to invasive breast cancer. This might help avoid unnecessary treatment for some women with DCIS in the future.
PARP inhibitors like olaparib are an exciting new avenue of targeted treatment for breast cancer patients with changes to the BRCA genes. Let’s look at the journey of olaparib from first experiments in the lab until now.